CIMZIA® label change marks an important advance for women in the UK of childbearing age with moderate to severe active rheumatoid arthritis
Published: 15 Jan 2018
The European Medicines Agency (EMA) has approved the label change for UCB’s CIMZIA® (certolizumab pegol), making it the first anti-TNF for potential use in women with moderate to severe active rheumatoid arthritis, active psoriatic arthritis and ankylosing spondylitis during both pregnancy and breastfeeding.
For more information, visit the UCB website here.
If you have rheumatoid arthritis and are considering pregnancy, you can also refer to our article here for additional information.